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Case Report
Orthotopic liver transplantation for Hepatitis C infection:
the best Christmas present?
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SUMMARY
We report the case ofa 60-year-old man with mild Christmas disease, Factor IX 10% ofnormal,
who developed chronic hepatitis C infection after receiving coagulation factor concentrates.
Subsequently he developed encephalopathy and liver failure and was referred for liver
transplantation.Followingtransplantation,FactorIXlevelsrapidlynormalisedandhaveremained
so, representing a phenotypic cure ofhis Christmas disease.
CASE REPORT
Thepatientoriginallypresented in 1971 (aged 35
years) with an episode of prolonged bleeding
fromthesiteofadentalextraction. Investigations
led to the diagnosis of mild Christmas disease
(Haemophilia B). Over subsequent years he was
given fresh frozen plasma and then intravenous
coagulation factor concentrates. In 1978, as part
of pre-operative management prior to
haemorrhoidectomy he was given coagulation
factor concentrates, and two weeks following
this he developed clinical jaundice with the




Thejaundice rapidly resolved although his liver
function tests remained abnormal. He had no
other risk factors for hepatitis C infection or for
the development of end-stage liver disease.
In May 1995 he presented with haematemesis
and melaena. Splenomegaly was noted on
examination, and upper gastrointestinal
endoscopy revealed large oesophageal varices
which were treated by a course of injection
sclerotherapy. He suffered several episodes of
encephalopathy without evidence of further
gastrointestinal bleeding, electrolyte imbalance
orinfection. In 1996hedevelopedfurtherepisodes
of encephalopathy and bleeding varices which
were again treated by injection sclerotherapy.
His clinical course was complicated by the
development of ascites which resolved with
spironolactone. Hecontinuedtohaveepisodes of
intermittent confusion and poor energy and was
managedwithoralspironolactone, neomycinand
lactulose. Liver biopsy was not performed. He
was unable to tolerate alpha-interferon treatment
on account of side-effects.
Hepatitis C antibody testing was positive and
hepatitis C RNA by PCR (Polymerase Chain
Reaction) was persistently positive with viral
subtype 3a.HbsAgnegative;HbeAg,HbeAbwere
negative. HBVcoreIgGwas notperformed. HIV
antibody test was negative. Autoimmune screen
revealedanti-smooth-muscle antibodyinlowtitre.
Haemoglobin wasreducedat 10.0g/dl, whitecell
count 4.1 x 109/1, platelets 163 x 109/1. Liver
function tests were as follow: albumin 29 g/l,
AST 56 U/i, ALP 216 U/1, bilirubin 28 mg/l,
alpha-fetoprotein normal. Creatinine clearance
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was normal (86 mls/min). Pulmonary function
tests and echocardiogram were normal.
Aminoacid profile at the time ofencephalopathy
revealed increased levels of tyrosine,
phenylalanine andmethionine, andnormal levels
ofvaline, leucine and isoleucine. Copper studies
andalpha-l-antitrypsin werenormal. Ultrasound
of the abdomen revealed patency of the portal
vein. CT brain scan was normal. Electro-
encephalogram revealed mild generalised
abnormality with slighttemporalpreponderance.
He was referred to King's College Hospital,
London, where he underwent an orthotopic liver
transplantation in October 1997. On the second
post-operative day he was found to have normal
Factor IX levels. He was subsequently treated
withcyclosporin, azathioprine, prednisolone and
sucralfate and remains well at six-month follow-




It is well-recognised that most haemophiliac
patients who have been given coagulation factor
concentrates prior to 1985 are at risk ofhepatitis
C infection. Interferon is the main treatment
currently available for chronic hepatitis C
infection and is commenced after a liver biopsy
confirms significant inflammatory changes
combinedwithevidenceofactiveviralreplication.
The risks of liver biopsy, in particular
haemorrhage, obviously are accentuated in
haemophiliacs who require coagulation factor
concentrates prior to the procedure, therefore
interferon treatment is often given without a
biopsy being undertaken. Liver biopsy may be
carried out inhaemophiliacs who areempirically
treated with interferon but who are unable to
tolerate the full course of treatment or if the
patients' symptoms suggest that they may have
significantliverdisease whichis notindicatedby
liver function tests. The main limitations of
interferontreatmentareadverseeffectsincluding
poor energy and flu-like symptoms as in this
case. Combination treatment is a possible
treatmentoptionforthefutureandfurtherstudies
are currently underway with amantidine and
ribavirin with interferon.
Haemophiliac patients with chronic hepatitis C
infection have acumulative riskofprogressing to
livercirrhosisin 1.7% at l0Oyears and 19.8% at2O
years' and liver transplantation may be required.
Successful liver transplantation in humans with
haemophiliawasinitiallydescribedinonepatient
with severe haemophilia A (Factor VIII
deficiency) in 1985.2 The procedure is safe
providingthatadequateintra-andimmediatepost-
operativecoagulationfactorreplacementisgiven
to avoid bleeding complications and there does
not appear to be an excessive transfusion
requirement.3 There are reports ofthree patients
with Haemophilia B (4-6), 10 patients with
Haemophilia A (3, 4, 7-9) and one patient with
combined factors VIII and IX deficiency10 who
have received liver transplants in the literature.
Data on the survival and length of cure of such
patientsislimited. Onereportdocuments survival
of 12 months post-transplantation and sustained
factor concentrations.4 There is one report of a
patient who died intra-operatively which was
relatedtotechnical difficulties ofgraftinsertion9
and one late mortality due to the development of
acquired immunodeficiency syndrome,8 another
complication of multitransfused haemophiliacs.
Liver transplantation has been used in the
treatment of genetic diseases in patients with no
significant liver disease.11 A case can be made
forlivertransplantationpriortothedevelopment
of liver failure in haemophiliac patients with
hepatitis C infection in view of the additional
benefits of a phenotypic cure of the clotting
abnormality.3 However, this must be viewed in
the light ofthe present shortage of organ donors
and the impact on other patients with end-stage
liver disease. The mechanism of cure of the
coagulation deficiency relates to the fact that the
liver is the source of synthesis of the vitamin K
dependent coagulation factors (including Factor
IX) and since the graft originated from a non-
haemophiliac patient there is a phenotypic cure
of the coagulation deficiency.
The main long-term problem with liver
transplantation for hepatitis C induced cirrhosis
is allograft reinfection with HCV, which usually
runsabenigncourse12althoughitmayprogress to
cirrhosis within 1-2 years.'3 The time taken for
therestoration ofnormalcoagulationfactors may
be as short as 12 hours4 and a sustained response
at72hoursconfirmsdenovosynthesisofclotting
factorsbythe graft. Furtherfollow-up is required
to determine if there is a sustained cure of the
haemophilia and to see the outcome of the
continuing HCV infection.
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